Delcath Systems (DCTH) Q3 2024 earnings summary

Executive summary

• Achieved $11.2 million in Q3 2024 revenue, up from $0.4 million in Q3 2023, driven by HEPZATO KIT U.S. launch and CHEMOSAT growth in Europe, marking a 44% sequential increase over Q2 2024.

• Net income of $1.9 million in Q3 2024 versus a net loss of $20.3 million in Q3 2023; nine-month net loss narrowed to $23.0 million from $36.5 million year-over-year.

• Ended Q3 with 12 active U.S. HEPZATO centers, expanding to 12 in October, and targeting 15 by year-end and 20 in Q1 2025.

• Publication of Phase 3 FOCUS Trial results and multiple independent studies support clinical adoption and reimbursement for CHEMOSAT and HEPZATO.

Financial highlights

• Q3 2024 gross profit was $9.6 million, up from $0.3 million in Q3 2023; gross margin reached 85% on $11.2 million revenue.

• Operating loss improved to $1.3 million in Q3 2024 from $10.6 million in Q3 2023; net income for Q3 2024 was $1.9 million.

• Cash and investments at quarter-end totaled $14 million, with $25 million added from warrant exercises post-Q3.

• Operating cash burn was $3.6 million in Q3; used $17.7 million in cash for operating activities in the first nine months of 2024.

Outlook and guidance

• Expect to exit 2024 with at least 15 treating centers and reach 20 in Q1 2025; goal of 30 centers by end of 2025.

• Plans to expand the development pipeline, including new HEPZATO trials in liver-dominant colorectal and breast cancers, with enrollment starting mid-2025 and late 2025.

• Anticipate seasonality in Q4 due to holidays, with 1.5–2 weeks fewer treatment days, but treatments are deferred, not lost.

• R&D expenses for 2025 projected at $35–$40 million, including new indication trials.

• Uncertainty remains regarding liquidity if site activation or revenue growth is delayed; additional capital may be needed.